3 minute read
Oct. 29, 2022

Upacicalcet: a CaSR Agonist Being Developed for SHPT

upacicalcet

IV CaSR agonist Ph. III candidate in secondary hyperparathyroidism identified from "kokumi-flavor" studies of peptides Mol. Pharmacol., Oct 1, 2022 Sanwa Kagaku Kenkyusho, Mie, JP

drughunter.com
Drug Hunter Team

Context. Upacicalcet (Sanwa Kagaku Kenkyusho Co) is a calcium-sensing receptor (CaSR) agonist being developed for secondary hyperparathyroidism (SHPT). The IV drug, first identified in "kokumi-flavor" studies of γ-glutamyl peptides, was approved for SHPT in Japan in 2021 and is currently being developed for the US and other markets [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in